Lin Brian C, Kaissarian Nayiri M, Kimchi-Sarfaty Chava
Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD, USA.
Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD, USA.
Trends Pharmacol Sci. 2023 Feb;44(2):73-84. doi: 10.1016/j.tips.2022.09.008. Epub 2022 Oct 25.
Synonymous gene recoding, the substitution of synonymous variants into the genetic sequence, has been used to overcome many production limitations in therapeutic development. However, the safety and efficacy of recoded therapeutics can be difficult to evaluate because synonymous codon substitutions can result in subtle, yet impactful changes in protein features and require sensitive methods for detection. Given that computational approaches have made significant leaps in recent years, we propose that machine-learning (ML) tools may be leveraged to assess gene-recoded therapeutics and foresee an opportunity to adapt codon contexts to enhance some powerful existing tools. Here, we examine how synonymous gene recoding has been used to address challenges in therapeutic development, explain the biological mechanisms underlying its effects, and explore the application of computational platforms to improve the surveillance of functional variants in therapeutic design.
同义基因编码,即将同义变体替换到基因序列中,已被用于克服治疗性开发中的许多生产限制。然而,编码治疗药物的安全性和有效性可能难以评估,因为同义密码子替换可能导致蛋白质特征发生细微但有影响的变化,并且需要灵敏的检测方法。鉴于近年来计算方法取得了重大进展,我们提出可以利用机器学习(ML)工具来评估基因编码治疗药物,并预见有机会调整密码子上下文以增强一些现有的强大工具。在这里,我们研究了同义基因编码如何被用于应对治疗性开发中的挑战,解释其作用背后的生物学机制,并探索计算平台在改善治疗设计中功能变体监测方面的应用。